According to the new market research report “In Vivo Toxicology Market by Product (Animal Models, Reagents & Kits), Test Type (Chronic, Sub-acute), Toxicity Endpoints (Systemic, Immunotoxicity), Testing Facility (Outsourced, In-house), End User (Academic & Research Institute, CROs) – Forecast to 2025″, published by MarketsandMarkets™, the global Toxicity Testing Market size is projected to reach USD 6.6 billion by 2025, at a CAGR of 5.5% between 2020 and 2025. Growth Opportunity: Rising demand for humanized animal models; Humanized animal models are important tools for conducting preclinical research to gain insights into human biology. These models are developed through the engraftment of human cells or tissues, leading to the expression of human proteins in animals. Humanized mice are increasingly being used as models for biomedical research applications, such as cancer, infectious diseases, HIV/AIDS, regenerative medicine, and hepatitis. In March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the US Department of Health and Human Services, announced funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The need to identify the actual effects of drugs on humans, as well as the growing focus on studying human-specific infections, therapies, and immune responses, is promoting the development and use of humanized animal models Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811 The Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine. Consumables accounted for the largest share in the in vivo toxicology market in 2019. Based on the product, the market is categorized into instruments and consumables. The consumables segment is further categorized into animal models and reagents & kits. Animal models is sub segmented into mice, rat and other animals. The consumables segment accounted for the largest share of the market in 2019. The widespread use of reagents & kits in research activities, increase in funds for research projects, and their extensive application in the in vivo toxicology studies are fueling the growth of this segment. Chronic test type accounted for the largest share in the toxicity testing market in 2019 Based on test type, segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type. Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market. Outsourced testing facilities accounted for the largest share in the in vivo toxicology market in 2019 Based on the testing facility, the global toxicity testing market is segmented into outsourced testing facilities and in-house testing facilities. The outsourced testing facilities segment is expected to dominate the market, by testing facility, over the forecast period. In 2019, the outsourced testing facilities segment held the largest share of the global market. The large share of this segment is attributed to the increasing R&D investments and cost-saving strategies of pharmaceutical, biopharmaceutical, and medical devices companies, resulting in increased outsourcing of services to CROs. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811 Academic and research institutes accounted for the largest share the market in 2019 Based on the end user, the global market has been broadly segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users (cosmetic companies and food laboratories). The academic and research institutes segment accounted for the largest share of the in vivo toxicology market in 2019. The increasing number of research activities in the field of in vivo toxicology and funding to the academic and research institutes to conduct in vivo toxicology research are the factors responsible for the largest share of the segment. North America accounted for the largest share of the toxicity testing market in 2019. Based on the region, the global in vivo toxicology market is segmented into North America, Europe, the Asia Pacific, Latin America and Middle East & Africa. In 2019, North America accounted for the largest share of the market. The large share of the North America region can be attributed to the presence of major players operating in the market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region. The major players operating in Toxicity Testing Market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others. Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=105308811
0 Comments
According to the new market research report “Hernia Repair Market by Product (Mesh (Synthetic, Biologic), Mesh Fixation (Suture, Tack and Glue Applicator)), Surgery Type (Inguinal, Incisional/Ventral, Umbilical, Femoral), and Geography (America, Europe, Asia Pacific) – Forecast to 2023″, published by MarketsandMarkets™, the hernia mesh market is projected to reach USD 4.75 Billion by 2023 from USD 4.09 Billion in 2018, at a CAGR of 3.0% during the forecast period. Recent Developments: – In 2017, BD acquired C. R. Bard. With this acquisition, BD entered the hernia repair business. The acquisition is expected to help C. R. Bard to increase its geographic presence in terms of both—sales and operations and maintain its market position. – In 2017, Allergan acquired LifeCell Corporation. This acquisition expanded its medical aesthetic products portfolio by the addition of ALLODERM and STRATTICE. – In June 2017, W. L. Gore GORE launched SYNECOR Preperitoneal Biomaterial. The newly launched product helped the company to broaden its product offerings in the hernia market – In 2016, B. Braun opened its new subsidiary in Zambia named ‘B. Braun Medical Zambia Limited’ which will help the company to establish a strong foothold in Southern Africa. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203245450 The rising adoption of mesh in hernia repair surgeries, rising geriatric population, new product developments, and favorable reimbursement scenario in developed countries are the major factors driving the growth of this market. The report analyzes and studies the patient population affected with hernia in the US, Canada, Germany, France, the UK, Japan, China, and India. Along with patient population, the report studies the adoption of synthetic and biologic mesh in hernia repair surgeries and the adoption of suture, tack, and glue applicators for mesh fixation. The hernia mesh segment is estimated to account for the largest share of the hernia mesh market On the basis of product, the hernia repair market is segmented into mesh and mesh fixators. A mesh is used for reinforcing weak spots in the muscle while repairing the hernia. Mesh fixators are used to fix the mesh in its place to avoid displacement. In 2018, the hernia mesh segment is expected to account for the largest share of the market. This large share can be attributed to the higher prices of meshes compared to mesh fixators. In 2018, tack applicators to account for the largest share of the mesh fixators market The hernia mesh fixators market is segmented into sutures, tack applicators, and glue applicators. Among these, sutures is the most common type of mesh fixator, followed by tack. However, due to the higher price of tacks, the tack applicators segment is expected to account for the largest share in the mesh fixators market in 2018. While the rising adoption of surgical glue as mesh fixators makes glue applicators the fastest growing segment of the mesh fixators market. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=203245450 In 2018, North America is projected to account for the largest market share The global hernia repair market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (RoW). In 2018, North America is estimated to account for the largest market for hernia mesh devices. The large share of North America in this market can be attributed to the strong demand for and adoption of hernia repair in the US, presence of a large pool of hernia patients, and an efficient and favorable healthcare system are supporting the growth of the hernia mesh market in North America. The major players in the hernia repair market profiled in this report are Covidien ( Part of Medtronic) (Ireland), Ethicon (Part of Johnson & Johnson) (US), B. Braun (Germany), C.R. Bard (Part of Becton Dickinson) (US), W. L. Gore (US), LifeCell (Part of Allergan) (Ireland), Maquet (Part of Getinge) (Sweden), Cook Medical (US), Integra (US), DIPROMED (Italy), FEG (Germany), Cousin Biotech (France), Herniamesh (Italy), Aspide Medical (France), TransEasy Medical (China), and Via Surgical (Israel). Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=203245450 According to the new market research report "Laboratory Information Management System (LIMS) Market by Type (Broad), Component (Software, Service), Delivery (On premise, Cloud, SaaS, PaaS, IaaS), Industry (CRO, CMO, Pharma, Biotech, Chemical, Agriculture, FnB, Oil, Gas) - Global Forecasts to 2026", published by MarketsandMarkets™, the global LIMS Market is projected to reach USD 2.1 billion by 2026 from an estimated USD 1.1 billion in 2021, at a CAGR of 13.2%. Opportunities: Significant growth potential in emerging markets; China, India, Japan, Singapore, Brazil, and Middle Eastern countries are major upcoming markets for LIMS. These markets lack proper standards and government regulations, thus offering huge potential for vendors unable to meet the standards implemented in developed markets such as the US. Several biopharma players are also shifting their manufacturing plants in Asia for low-cost production. This is creating significant demand for informatics solutions in Asian countries. However, the COVID-19 pandemic has compelled stakeholders from developed markets such as the US and Europe to reduce their heavy dependence on Asian countries and shift back to in-house operations. Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=250610373 The Growth of this Laboratory Information Management System Market is attributed to the increasing use of LIMS to comply with stringent regulatory requirements, rising need for the adoption of LIMS, technological advancements in LIMS offerings, increasing R&D expenditure in different industries, and growing adoption of cloud-based LIMS. The companies have a large market spread across various countries in North America, Europe, Asia Pacific, and the Rest of the World. Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Largely unknown before the outbreak began in Wuhan, China, in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. The state of urgency to combat the outbreak led pharma & biotech companies, researchers, various diagnostic labs, and testing facilities conducting COVID-19 research to adopt advanced technologies and solutions exceeding traditional avenues to improve workflows. Research laboratories or diagnostic labs focusing on COVID-19 research need to handle multiple steps (such as test management, sample handling, inventory control, packaging, and shipment). Also, research laboratories focused on developing treatments or vaccines for COVID-19 need an effective end-to-end solution to improve the quality, productivity, and rapidity of the vaccine manufacturing process. This is likely to increase the uptake of informatics solutions, such as LIMS, which enhance research and testing activities, along with efficient data management. Industry-specific LIMS segment is projected to record the highest CAGR Based on type, the LIMS market is segmented into broad-based LIMS and industry-specific LIMS. The broad-based LIMS segment accounted for the largest share of the market in 2020. Broad-based LIMS solutions provide users with significant room for customization and interpretation that can support multiple businesses across different geographic locations; these factors are driving the adoption of broad-based LIMS. Furthermore, broad-based LIMS solutions also help streamline laboratory workflow processes and improve decision-making and reporting. Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=250610373 Services segment is expected to register the highest growth during the forecast period Based on the component, the LIMS market is segmented into software and services. Services accounted for the largest share of the Laboratory Information Management System Market in 2020. This segment is projected to register the highest CAGR during the forecast period. The large share of the services segment can be attributed to the recurring requirement of services, such as training, software upgradation, and software maintenance post-installation. Cloud based segment is estimated to record the highest CAGR in the forecast period. Based on the deployment model, the LIMS market is segmented into on-premise, cloud-based, and remotely hosted LIMS. In 2020, the on-premise LIMS segment commanded for the largest share of the market. The large share of this segment can be attributed to the fact that these solutions are more customizable and have minimum risk associated with data breaches and external attacks. Life sciences segment is estimated to record the highest CAGR in the forecast period. Based on industry, the LIMS market is broadly segmented into seven categories-life sciences, chemical, food & beverage and agriculture, environmental testing, petrochemical refineries and oil & gas, forensics, and other industries. Life sciences commanded the largest share of the Laboratory Information Management System Market, by industry, in 2020. Factors such as growth in the outsourcing of various pharma and biotech processes, increasing stringency of regulations, the increasing number of biobanks/biorepositories, and growing R&D investments/activities in pharmaceutical and biotechnology companies are responsible for the growth of this segment. Speak to Analyst:https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=250610373 North America to Witness Significant Growth from 2021 To 2026 In 2020, North America commanded the largest share of the Laboratory Information Management System (LIMS) Market, followed by Europe. North America's dominance in the market can be attributed to the strong economies of the US and Canada, which have allowed for significant investments in new technologies, growth in biobanks, easy availability of LIMS products and services, and stringent regulatory requirements across industries. The prominent players operating in the Laboratory Information Management System Market are LabWare (US), LabVantage Solutions (US), Thermo Fisher Scientific (US), Abbott Informatics (US), Agilent Technologies Inc. (US), LabLynx, Inc. (US), Dassault Systèmes (France), Labworks LLC (US), Autoscribe Informatics (US), and Accelerated Technology Laboratories (ATL). According to the new market research report “Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instrument), Technique (Flow Cytometry, NGS, PCR, Microscopy, MS), Application (Research, Medical), End User (Pharma, Biotech, Hospitals) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 6.3 billion by 2026 from USD 3.1 billion in 2021, at a CAGR of 15.1% during the forecast period. Growth Driver: Growing prevalence of cancer; One of the most important application areas of single-cell analysis is cancer genomics. According to GLOBOCAN, the number of cancer cases will rise to approximately 30 million by 2040 from 19.3 million cases and 10 million cancer deaths in 2020. The growth in the prevalence of this disease has resulted in a need to conduct extensive research for diagnosis and treatment; single-cell analysis forms an important part of this research. The analysis of individual cells enables the correct diagnosis of diseases and monitoring of treatment efficacy. Single-cell analysis aids in the enumeration of helper T-cells, determination of DNA content, and monitoring the proliferation of tumor cells in breast cancer and other malignancies. Recent Developments: - In March 2021, Beckman Coulter (a subsidiary of Danaher Corporation) launched the CytoFLEX SRT Benchtop Sorter that features expanded laser and color options for use in labs of all sizes. - In March 2020, Fluidigm Corporation (US) opened a new Center of Excellence (CoE) for Imaging Mass Cytometry (IMC) in Singapore, together with the Singapore Immunology Network (SIgN), part of the Agency for Science, Technology and Research.. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254 The Growth in the single-cell analysis market is driven by factors such as technological advancements in single-cell analysis products coupled with increasing R&D in the pharmaceutical and biotechnology industries, growing focus on personalized medicine, growth in stem cell research, and the rising prevalence of cancer. The consumables segment accounted for the largest share of the product segment in the single-cell analysis market in 2020. Consumables accounted for the largest share of the market in 2020. The large share of this segment can primarily be attributed to the frequent purchase of these products compared to instruments, which are considered a one-time investment. The wide applications of consumables in research and genetic exploration, exosome analysis, and isolation of RNA and DNA are also expected to drive market growth. The research applications segment accounted for the largest share of the application segment in the market in 2020 Based on applications, the single-cell analysis market is segmented into research and medical applications. The research applications segment accounted for the largest share of the market in 2020. Increasing government initiatives in stem cell research and the wide usage of single-cell analysis in cancer research are the major factors driving the growth of the research applications segment. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254 The Asia Pacific region is the fastest-growing region of the market in 2020. The market in the Asia Pacific is expected to grow at the highest CAGR of 17.4% during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in this region, rising geriatric population, rising prevalence of cancer, and increasing government initiatives. The prominent players in the single-cell analysis market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck KGAA (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Illumina, Inc. (US), Fluidigm Corporation (US), 10X Genomics (US), and Corning Incorporated (US). Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=171955254 According to the new market research report "Breast Reconstruction Market by Product (Breast implant, Tissue Expander, Acellular Dermal Matrix), Procedure (Immediate, Delayed, Revision), Type (Unilateral, Bilateral), End User (Hospitals, Cosmetology Clinics) - Global Forecast to 2026", published by MarketsandMarkets™, is projected to reach USD 647 million by 2026 from USD 567 million in 2021, at a CAGR of 2.7%from 2021 to 2026. Recent Developments:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186501593 The rising incidence of breast cancer and the availability of reimbursement for breast reconstruction are major driving factors for the market. Moreover, the development of 3D-printed breast implants is expected to offer significant growth opportunities to market players in the coming years. Breast implants accounted for the largest share of the breast reconstruction market Based on the product, the market is segmented into breast implants, tissue expanders, and acellular dermal matrix. The breast implants segment accounted for the largest market share in 2020. The immediate procedures segment accounted for the largest market share in 2020. Based on the procedure, the market is segmented into immediate, delayed, and revision procedures. The immediate procedures segment accounted for the largest market share in 2020. This is primarily attributed to the increasing number of surgeries post-mastectomy and rising awareness. The unilateral segment accounted for the largest market share in 2020. Based on type, the breast reconstruction market is segmented into unilateral and bilateral. The unilateral segment accounted for the largest market share in 2020. The increasing incidence of breast cancer and rising awareness are major factors responsible for the dominant share of this segment. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186501593 North America was the largest regional segment of the breast reconstruction market in 2020. By region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest market share, followed by Europe. This is attributed to factors such as the rising incidences of breast cancer, increasing awareness of breast reconstruction, and technology advancement and quality improvement leads to FDA approvals for breast reconstruction products The prominent players operating in the global breast reconstruction market are Mentor Worldwide LLC (Johnson & Johnson) (US), Allergan Aesthetics (an Abbvie company) (US), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), POLYTECH Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (US), and Silimed (Brazil). Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=186501593 According to the new market research report “Breath Analyzer Market by Technology (Fuel Cell, Semicoductor Oxide Sensor, Others), End User (Law Enforcement Agencies, Enterprises, Individuals ), Application, Region (North America, Europe, APAC, RoW) – Global Forecast to 2025″, published by MarketsandMarkets™, the breathalyzers market is expected to reach USD 1,167 million by 2025 from USD 524 million in 2020, at a CAGR of 17.4% during the forecast period. Opportunities: Technological advancements; The breath analyzers market is technology-driven and is projected to grow at a significant rate in the coming years. Owing to the lucrative potential of the market, a number of players are focusing on developing novel technologies and are continuously introducing accurate and easy-to-use breath analyzers. In August 2019, Y Combinator, an investment company, invested in SannTek Labs to work on a new kind of breathalyzer. This breathalyzer is designed to detect blood alcohol levels as well as the type of cannabis a person has consumed in the past 3 to 4 hours. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=57484012 The Growth in the market can primarily be attributed to factors such as alcohol and drug abuse, stringent government regulations and increasing use of breath alyzers in detecting various diseases. By technology, the fuel cell segment is expected to account for the largest share of the market in 2020 Based on technology, the breath analyzers market is segmented into fuel cells, semiconductor oxide sensors, and other technologies (infrared spectroscopy and chemical crystals). In 2020, the fuel cells segment accounted for the largest share of the global market. Fuel cells are the most widely used technology in breath analyzers. Fuel cell-based breath analyzers offer an extremely high level of accuracy, sensitivity, and reliability. They are specifically tuned to detect alcohol and do not require multiple sensors. These analyzers are considered the gold standard of handheld alcohol testers for both personal and professional use. By application, the alcohol detection segment is expected to account for the largest share of the market in 2020 On the basis of application, the breath analyzers market is segmented into alcohol detection, drug abuse detection, and medical applications. The alcohol detection segment accounted for the largest market share in 2020. This segment is also projected to register the highest CAGR during the forecast period. The growth of this segment is primarily driven by stringent government regulations for driving under the influence (DUI). By end user, the law enforcement agencies segment is expected to account for the largest share of the breath analyzer market in 2020 Based on end users, the breathalyzers market segmented into law enforcement agencies, enterprises, and individuals. In 2020, the law enforcement agencies segment accounted for the largest share of the global market. Stringent safety laws against DUI and the rising scale of screening and evidential testing are driving the adoption of breath analyzers in law enforcement. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=57484012 Asia-Pacific to witness the highest growth rate in 2020 Based on region, the breath analyzer market is segmented into North America, Asia-Pacific, Europe and Rest of the world (RoW). Asia Pacific is expected to register the highest CAGR during the forecast period. The major factors driving the growth of the Asia Pacific market include as growing consumption of alcohol, increasing research on the medical applications of breath analyzers, and the development of advanced breath analyzers. The prominent players in the global breath analyzer market include Drägerwerk AG & Co. KGaA (Germany), MPD, Inc (US), Lifeloc Technologies (US), BACtrack, Inc. (US), Quest Products, Inc. (US), Akers Biosciences, Inc. (US), Intoximeter, Inc. (US), AK GlobalTech Corporation (US), Alcohol Countermeasure Systems Corporation (Canada), EnviteC-Wismar GmbH (Germany), Lion Laboratories Ltd. (UK) Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=57484012 According to the new market research report “Surface Disinfectant Market by Composition (Quaternary Ammonium, Alcohols, Chlorine, Hydrogen Peroxide), Type (Liquids, Sprays, Wipes), Application (Surface, Instrument), End User (Hospitals, Diagnostic and Research Labs) – Global Forecast to 2025″, published by MarketsandMarkets™, is projected to reach USD 3.6 billion by 2025 from USD 3.1 billion in 2020, at a CAGR of 3.0% from 2020 to 2025. Driver: Rising number of stringent regulations for the use of surface disinfectants; Rising number of stringent regulations focus on the development of suitable policies for housekeeping services, which puts a premium on good housekeeping and sanitation. Such regulatory guidelines will help in improving the regular usage of surface disinfectants across healthcare settings. Opportunity: Increasing healthcare expenditure and focus in emerging economies; Emerging economies, such as India, Brazil, and South Africa, provide significant opportunities for players in the sterilization and disinfection markets. Emerging economies in the APAC region present lucrative investment opportunities for multinational infection control companies to offshore their business operations to these markets. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2312860 The growth of this market is majorly driven by the increasing prevalence of hospital-acquired infections (HAIs) globally, presence of stringent regulations for the use of surface disinfectants (in hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, and research laboratories), and advancements in surface disinfectants. Alcohols segment accounted for the largest share of the surface disinfectants market. On the basis of composition, the market is segmented into alcohols, chlorine compounds, quaternary ammonium compounds, hydrogen peroxide, peracetic acid, and other compositions. In 2019, the alcohols segment accounted for the largest market share. The high use of alcohols on hard surfaces in hospitals and laboratories is driving the growth of this segment. Other segments, such as hydrogen peroxide and peracetic acid are expected to have higher growth rates due to their growing acceptance in surface disinfectant formulations. Liquids segment accounted for the largest share of the of the surface disinfectants market. On the basis of type, the market is segmented into liquids, wipes, and sprays. The liquids segment accounted for the largest market share in 2019. This can primarily be attributed to the wide usage of these disinfectants, especially in emerging and underdeveloped countries, due to their low cost. The hospital settings segment is expected to dominate the market in 2020. By end user, the surface disinfectants market is segmented into hospital settings, diagnostic laboratories, pharmaceutical & biotechnology companies, and research laboratories. In 2019, hospital settings accounted for the largest share of the market. The large share of this segment can be attributed to factors, such as the high prevalence of infections in hospitals, the increase in hospital reimbursements for surgeries performed in hospitals, and growing patient volume in these healthcare settings. Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231286043 The surface disinfection segment dominated the market in 2019. The surface disinfectants market, by application, is segmented into surface disinfection, instrument disinfection, and other applications. In 2019, the surface disinfection segment accounted for the largest share of the market. The large share of this segment can primarily be attributed to the large volume of disinfectants required to clean in-house surfaces in healthcare settings. Based on region, the surface disinfectant market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America commanded the largest share of the market. The large share of this market segment can be attributed majorly to the high prevalence of HAIs and the presence of stringent infection control regulations in the region. The major players operating in this surface disinfectant market are 3M Group (US), Cantel Medical Corporation (US), The Clorox Company (US), Ecolab Inc. (US), Procter & Gamble (US), Reckitt Benckiser Group plc. (UK), Diversey, Inc. (US), STERIS plc (US), CarrollCLEAN (US), Metrex Research, LLC. (US), Whiteley Corporation (Australia), GOJO Industries, Inc. (US), PAUL HARTMANN AG (Germany), Medline Industries, Inc. (US), Pharmax Limited (Canada), PDI Inc. (US), Betco (US), GESCO Healthcare Pvt. Ltd. (India), MEDALKAN (Greece), Ruhof (US), Contec Inc. (US), Cetylite, Inc. (US), Micro-Scientific, LLC (US), Pal International (UK), and BHC, Inc. (US). Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=231286043 According to the new market research report “Prefilled Syringes Market by Type [Conventional (Disposable, Reusable), Safety], Material (Glass, Plastic), Design (Single-Chamber, Dual-Chamber, Customized), Application (Diabetes, Cancer, Arthritis, Anaphylaxis, Ophthalmology) – Global Forecast to 2025″, published by MarketsandMarkets™, is estimated to be USD 5.6 billion in 2020 and projected to reach USD 8.6 billion by 2025, at a CAGR of 9.0%. Opportunity: Growing healthcare infrastructure across emerging markets; Emerging countries continue to suffer from insufficient healthcare funding, which adversely affects access to healthcare, quality, and, ultimately, the health status of citizens. According to the World Bank, approximately 400 million people lack access to essential healthcare services, mostly in Africa and South Asia. Furthermore, accelerating medical inflation, i.e., the cost of medical treatments and a higher prevalence of non-communicable lifestyle-related diseases such as cancer, diabetes, or cardiac syndromes, have resulted in funding gaps. According to a report published by Geneva Association, in the last two decades, the share of total aggregate global expenditure on healthcare in GDP has increased from about 8% to almost 10%, or an estimated USD 8 trillion per annum, which is driven by the accelerating cost of medical treatment, expanding treatment options and increasing customer demands. Moreover, the Global Burden of Disease Health Financing Collaborator Network (2017) estimates that global spending on health will almost triple to USD 24 trillion by 2040 with upper-middle-income countries are estimated to show the fastest increase at an average of 5.3% per year. This growth could be attributed to continued growth in GDP and the rise of the middle class and government spending. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=16618331 The Rising target disease population, rapid growth in generic products, rising adoption of self-medication and digitalization, affordable cost with increased efficiency, and technological advancements are the major factors driving the growth of the market. Furthermore, growing initiatives undertaken by leading market players to establish production facilities in both mature and developing markets are the key factors driving the growth of the prefilled syringes industry. The Prefilled Syringes Market includes major Tier I and II suppliers like Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), and West Pharmaceutical Services, Inc. (US), and Nipro Corporation (Japan). These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Routine care for chronic diseases is an ongoing challenge amidst the global COVID-19 pandemic due to the change in routine care to virtual communication. Diabetes, chronic obstructive pulmonary disease, and hypertension were the most impacted conditions due to a reduction in access to care. Furthermore, currently, most global healthcare resources are focused on coronavirus disease (COVID-19), and this resource reallocation is expected to disrupt the continuum of care for patients with chronic diseases. Increasing adoption of self-administered injectable drugs is expected to result in the segment occupying the majority of the market share The conventional Prefilled Syringes Market is estimated to have the largest market share by value. Growth of this segment can be attributed to the the advantages offered, such as safe administration, ease of use for both healthcare professionals and end users, reduced risk of contamination of the product, less waste of costly API, ease of manufacturing, improved dosing accuracy, and enhanced product differentiation when compared to vials is expected to drive the market growth. Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=16618331 Plastic Prefilled Syringes estimated to be the fastest-growing market Plastic prefilled syringes are estimated to be the fastest-growing segment in the Prefilled Syringes Market. The growth of this segment can be attributed to the rising development of newer polymers (which possess various physical and chemical properties such as high heat & break resistance, tolerance of freeze-drying & liquid nitrogen exposure, high transparency, and solvent resistance. Europe is estimated to be the largest market due to the rising prevalence of chronic diseases, growth of the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, aging population, and high adoption of self-injection devices are driving the demand for self-injectable prefilled syringes. Asia Pacific likely to emerge as the largest Prefilled Syringes Market. Asia Pacific is estimated to be the fastest-growing market for prefilled syringes during the forecast period. The Asia Pacific market is driven principally by the increasing demand for self-administered treatments, high penetration of self-injection devices, growing aging population, increasing prevalence of diabetes, and huge patient population. Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), and West Pharmaceutical Services, Inc. (US) are the key players in the global Prefilled Syringes Market Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=16618331 According to the new market research report "Digital Pathology Market by Product( Artificial Intelligence, Scanner, Software, Storage), Type(Human, Veterinary), Application( Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User( Pharma, Academia, Hospitals ) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period. Browse and in-depth TOC on "Digital Pathology Market" 279 - Tables 43 - Figures 257 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844 The growth in the Digital Pathology Market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics. On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent. The scanners segment accounted for the largest share of the Digital Pathology Market in 2020. Based on products, the market has been segmented into scanners, software, and storage systems. The large share of the scanners segment can be attributed to the high price of scanners and the increasing adoption of digital pathology solutions. The human pathology segment accounted for the largest share of the Digital Pathology Market in 2020. Based on type, the global market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of the market in 2020. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=844 The drug discovery, segment accounted for the largest share of the Digital Pathology Market in 2020. Based on application, the market is segmented into drug discovery, disease diagnosis, and training & education. The drug discovery segment accounted for the largest share of the market in 2020. Growth in R&D expenditure fueled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process is a major factor responsible for market growth. The pharmaceutical & biotechnology companies, segment accounted for the largest share of the Digital Pathology Market in 2020. Based on end users, the global market is segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. The pharmaceutical & biotechnology companies segment accounted for the largest share of the Digital Pathology Market in 2020. The large share of this segment can be attributed to the increasing use of digital pathology for drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine. Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=844 The market in North America is projected to witness the highest growth rate during the forecast period (2021–2026). North America accounted for the largest share of the Digital Pathology Market in 2020. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the governments in the US and Canada are major factors driving the growth of the market in North America. The major players in the global Digital Pathology Market include Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (US), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Inspirata, Inc. (US), PathAI (US), Proscia Inc. (US), Kanteron Systems (Spain), Mikroscan Technologies (US), Motic (US), and Paige (US). The report "Fractional Flow Reserve Market by Technology (Invasive Monitoring, Non-invasive Monitoring), Invasive Monitoring Product (Pressure Guidewires, FFR Measurement Systems), Application, and Region - Global Forecast to 2024", is projected to reach USD 1,081.8 million by 2024 from USD 516 million in 2019, at a CAGR of 16.0% during the forecast period. Driver: Rising geriatric population and the subsequent growth in the prevalence of CVD; Over the years, there has been a significant increase in the geriatric population across the globe. According to the UN World Population Ageing Report 2017, the global geriatric population (aged 60 years and above) is expected to reach 2.1 billion by 2050 from 962 million in 2017. As this population segment is highly susceptible to CVD and other target diseases, the demand for advanced diagnostic and treatment options is expected to increase in the coming years. Changing lifestyle, smoking, hypertension, high blood cholesterol levels, physical inactivity, high BMI, and high blood sugar levels are the leading risk factors for heart disease and stroke. With the rising prevalence of CVD, the number of related diagnostic and treatment procedures is expected to increase significantly across the globe in the coming years. In this scenario, the demand for fractional flow reserve is likely to increase as it provides various benefits, such as assessing if the stenosis is required, which in turn helps in avoiding surgeries (in cases where stenosis is not needed). Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=257837023 Leading Key Players and Analysis: The key players in the fractional flow reserve market are Abbott (US), Boston Scientific (US), ACIST Medical Systems (US), Koninklijke Philips N.V. (Netherlands), Opsens, Inc. (Canada), HeartFlow, Inc. (US), Siemens Healthineers (Germany), Pie Medical Imaging (Netherlands), CathWorks (Israel), and Medis Medical Imaging Systems BV (Netherlands). Abbott (US) held the leading position in the fractional flow reserve market. The company acquired a significant share in the FFR market through the acquisition of St. Jude Medical (US). This acquisition positioned Abbott as a major cardiology devices provider. The strategic acquisition of St. Jude Medical, a leading player in the cardiovascular and neuromodulation products market, strengthened the position of Abbott in the fractional flow reserve (FFR) market. Abbott focuses on continuous expansions to achieve optimal growth across industries and different geographic areas. It strives to maintain its position through innovation and product launches. For instance, the company invests a significant amount of its revenue in R&D activities to increase its presence in the market. It invested USD 2.30 billion, USD 2.26 billion, and USD 1.42 billion on R&D in 2018, 2017, and 2016, respectively Geographical Analysis in Detailed? Asia Pacific to register the highest CAGR during the forecast period North America dominated the FFR Market in 2018. The large share of the North American fractional flow reserve market can primarily be attributed to the high healthcare spending in the region, rising prevalence of CVD and lifestyle diseases, growth in the geriatric population, large number of ongoing research activities and product launches, availability of reimbursements, and the rapid adoption of technologically advanced imaging systems. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=257837023 Industry Segmentation: The invasive monitoring segment to account for the largest market share during the forecast period Based on technology, the fractional flow reserve market is segmented into invasive and non-invasive monitoring. The invasive monitoring segment accounted for the largest share of the market in 2018 and will continue to do so during the forecast period. Invasive FFR monitoring is considered the gold standard for determining the hemodynamic impact of coronary lesions. This technology utilizes pressure guidewires and monitoring systems for the measurement of fractional flow reserve. The pressure guidewire measures the flow and pressure of the blood before and after the blockage to produce a ratio. The single-vessel diseases segment will dominate the market during the forecast period. Based on application, the FFR Market is segmented into single-vessel diseases and multi-vessel diseases. In 2018, the single-vessel disease segment accounted for the larger share of the fractional flow reserve market. The large share of this segment can be attributed to the high prevalence of single-vessel coronary artery disease. The pressure guidewires segment is expected to grow at the highest CAGR during the forecast period On the basis of product, the invasive monitoring market is segmented into pressure guidewires and FFR monitoring systems. The pressure guidewires segment accounted for the largest share of the market in 2018. This can be attributed to the growth in the number of PCI procedures (as a result of the rising prevalence of CVD), strong recommendation for the use of guided revascularization by measuring FFR in specific clinical scenarios, and the single-use nature of pressure guidewires, which ensures repeat purchases. Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=257837023 |
AuthorResearch Analyst in Healthcare Archives
August 2021
Categories |